A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This is a Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects with Previously Treated Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma to compare the progression free survival (PFS) and overall survival (OS)
Inclusion Criteria:
Exclusion Criteria:
Wuhan, Hubei 430000, China
Shanghai, Shanghai Municipality 200001, China
Hangzhou, Zhejiang 310003, China
Kashiwa-shi, Chiba 277-8577, Japan
Ota-Shi, Gunma 373-8550, Japan
Kure, Hirosima [Hiroshima] 737-0023, Japan
Osaka, Osaka 541-8567, Japan
Osakasayama-Shi, Osaka 589-8511, Japan
Suita-shi, Osaka 565-0871, Japan
Hidaka-Shi, Saitama 350-1298, Japan
Kitaadachi-Gun, Saitama 362-0806, Japan
Bunkyō-Ku, Tokyo 113-8655, Japan
Bunkyō-Ku, Tokyo 113-8677, Japan
Koto, Tokyo 135-8550, Japan